Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 10:25
12/01/22
12/01
10:25
12/01/22
10:25
ACET

Adicet Bio

$18.31 /

+0.12 (+0.66%)

, ACLX

Arcellx

$20.08 /

+0.12 (+0.60%)

, ALLO

Allogene Therapeutics

$9.46 /

-0.38 (-3.86%)

, BMY

Bristol-Myers

$80.52 /

+0.33 (+0.41%)

, CELU

Celularity

$1.78 /

+0.08 (+4.71%)

, CLLS

Cellectis

$2.22 /

+0.01 (+0.45%)

, CRBU

Caribou Biosciences

$9.18 /

-0.145 (-1.55%)

, CRSP

Crispr Therapeutics

$54.83 /

+0.04 (+0.07%)

, DTIL

Precision BioSciences

$1.37 /

+0.01 (+0.74%)

, FATE

Fate Therapeutics

$20.93 /

+0.1 (+0.48%)

, GILD

Gilead

$88.72 /

+0.87 (+0.99%)

, GRCL

Gracell

$3.32 /

+0.07 (+2.15%)

, IPSC

Century Therapeutics

$10.45 /

-0.02 (-0.19%)

, JNJ

Johnson & Johnson

$178.00 /

+0.03 (+0.02%)

, LEGN

Legend Biotech

$51.29 /

-0.035 (-0.07%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.43 /

-0.03 (-0.35%)

, PSTX

Poseida Therapeutics

$4.63 /

+0.09 (+1.98%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.78 /

+0.08 (+4.71%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$88.72 /

+0.87 (+0.99%)

12/01/22 Oppenheimer
Gilead price target raised to $105 from $95 at Oppenheimer
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
GRCL Gracell
$3.32 /

+0.07 (+2.15%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
ACET

Adicet Bio

$18.20 /

+0.42 (+2.36%)

, ACLX

Arcellx

$19.90 /

+ (+0.00%)

, ALLO

Allogene Therapeutics

$9.84 /

+0.56 (+6.03%)

, BMY

Bristol-Myers

$80.19 /

+1.18 (+1.49%)

, CELU

Celularity

$1.71 /

+0.035 (+2.10%)

, CLLS

Cellectis

$2.22 /

+0.04 (+1.83%)

, CRBU

Caribou Biosciences

$9.33 /

+0.985 (+11.81%)

, CRSP

Crispr Therapeutics

$54.69 /

+1.78 (+3.36%)

, DTIL

Precision BioSciences

$1.36 /

+0.06 (+4.62%)

, FATE

Fate Therapeutics

$20.84 /

+1.07 (+5.41%)

, GILD

Gilead

$87.85 /

+2.09 (+2.44%)

, GRCL

Gracell

$3.28 /

+0.04 (+1.23%)

, IPSC

Century Therapeutics

$10.48 /

+0.14 (+1.35%)

, JNJ

Johnson & Johnson

$177.94 /

+1.895 (+1.08%)

, LEGN

Legend Biotech

$51.25 /

+2.64 (+5.43%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.46 /

+0.365 (+4.51%)

, PSTX

Poseida Therapeutics

$4.54 /

+0.125 (+2.83%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$19.90 /

+ (+0.00%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.71 /

+0.035 (+2.10%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$87.85 /

+2.09 (+2.44%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
GRCL Gracell
$3.28 /

+0.04 (+1.23%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
11/28/22 Morgan Stanley
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

Over a week ago
Hot Stocks
Bristol-Myers, Envisagenics announce research collaboration » 08:03
11/29/22
11/29
08:03
11/29/22
08:03
BMY

Bristol-Myers

$79.13 /

+ (+0.00%)

Envisagenics, an…

Envisagenics, an Artificial Intelligence-driven biotechnology company that delivers therapies for RNA splicing diseases, announced a research collaboration agreement with Bristol Myers Squibb. The multi-year collaboration will leverage Envisagenics' SpliceCore AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.

ShowHide Related Items >><<
BMY Bristol-Myers
$79.13 /

+ (+0.00%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
BMY Bristol-Myers
$79.13 /

+ (+0.00%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 16:34
11/28/22
11/28
16:34
11/28/22
16:34
ACET

Adicet Bio

$16.71 /

-0.41 (-2.39%)

, ACLX

Arcellx

$20.13 /

-1.52 (-7.02%)

, ALLO

Allogene Therapeutics

$10.27 /

-0.515 (-4.78%)

, BMY

Bristol-Myers

$79.13 /

+ (+0.00%)

, CELU

Celularity

$1.63 /

+0.04 (+2.52%)

, CLLS

Cellectis

$2.24 /

-0.11 (-4.68%)

, CRBU

Caribou Biosciences

$8.53 /

-0.32 (-3.62%)

, CRSP

Crispr Therapeutics

$53.39 /

-1.54 (-2.80%)

, DTIL

Precision BioSciences

$1.35 /

-0.045 (-3.23%)

, FATE

Fate Therapeutics

$19.28 /

-0.54 (-2.72%)

, GILD

Gilead

$85.23 /

-1.04 (-1.21%)

, GRCL

Gracell

$3.13 /

-0.475 (-13.18%)

, IPSC

Century Therapeutics

$10.35 /

-0.15 (-1.43%)

, JNJ

Johnson & Johnson

$177.31 /

+0.11 (+0.06%)

, LEGN

Legend Biotech

$48.12 /

+0.09 (+0.19%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.09 /

-0.525 (-6.10%)

, PSTX

Poseida Therapeutics

$4.06 /

-0.34 (-7.73%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$79.13 /

+ (+0.00%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.63 /

+0.04 (+2.52%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$85.23 /

-1.04 (-1.21%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
GRCL Gracell
$3.13 /

-0.475 (-13.18%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
11/02/22 Morgan Stanley
Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/22 Deutsche Bank
Abiomed downgraded to Hold from Buy at Deutsche Bank
11/01/22 Piper Sandler
Abiomed downgraded to Neutral from Overweight at Piper Sandler
LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

On The Fly
Biotech Alert: Searches spiking for these stocks today » 10:27
11/21/22
11/21
10:27
11/21/22
10:27
CTMX

CytomX Therapeutics

$1.73 /

+ (+0.00%)

, AGIO

Agios Pharmaceuticals

$28.81 /

+0.59 (+2.09%)

, LCTX

Lineage Cell Therapeutics

$1.45 /

+0.02 (+1.40%)

, EDIT

Editas Medicine

$10.62 /

-0.335 (-3.06%)

, IMUX

Immunic

$1.39 /

-0.015 (-1.07%)

, ABBV

AbbVie

$156.50 /

+1.5 (+0.97%)

, BMY

Bristol-Myers

$78.11 /

+0.64 (+0.83%)

, AMGN

Amgen

$289.92 /

+2.63 (+0.92%)

, RHHBY

Roche

$40.15 /

-0.03 (-0.07%)

, REGN

Regeneron

$730.87 /

-8.72 (-1.18%)

These names in the…

ShowHide Related Items >><<
RHHBY Roche
$40.15 /

-0.03 (-0.07%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

LCTX Lineage Cell Therapeutics
$1.45 /

+0.02 (+1.40%)

IMUX Immunic
$1.39 /

-0.015 (-1.07%)

EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

CTMX CytomX Therapeutics
$1.73 /

+ (+0.00%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

AGIO Agios Pharmaceuticals
$28.81 /

+0.59 (+2.09%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

CTMX CytomX Therapeutics
$1.73 /

+ (+0.00%)

11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/10/22 JPMorgan
JPMorgan double downgrades 'show-me-story' CytomX Therapeutics
11/10/22 JPMorgan
CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan
07/11/22 Cowen
CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen
AGIO Agios Pharmaceuticals
$28.81 /

+0.59 (+2.09%)

11/17/22 Goldman Sachs
Agios Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
07/27/22 SVB Securities
Agios Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
02/25/22 RBC Capital
Agios Pharmaceuticals price target raised to $67 from $61 at RBC Capital
02/24/22 H.C. Wainwright
Agios Pharmaceuticals price target lowered to $96 from $98 at H.C. Wainwright
LCTX Lineage Cell Therapeutics
$1.45 /

+0.02 (+1.40%)

11/01/22 Baird
Baird starts Lineage Cell Therapeutics with an Outperform, $5 price target
11/01/22 Baird
Lineage Cell Therapeutics initiated with an Outperform at Baird
06/14/22 B. Riley
B. Riley starts 'deep value play' Lineage Cell with Buy, $4 target
06/14/22 B. Riley
Lineage Cell Therapeutics initiated with a Buy at B. Riley
EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
11/18/22 Truist
Editas Medicine price target lowered to $35 from $80 at Truist
IMUX Immunic
$1.39 /

-0.015 (-1.07%)

10/21/22 SVB Securities
Immunic downgraded to Market Perform from Outperform at SVB Securities
09/19/22 H.C. Wainwright
Immunic assumed with a Buy at H.C. Wainwright
06/02/22 Roth Capital
Roth suggests accumulating Immunic shares on pullback
06/02/22 Wedbush
Immunic price target lowered to $14 from $61 at Wedbush
ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

11/17/22 Credit Suisse
AbbVie initiated with an Outperform at Credit Suisse
11/08/22 Societe Generale
AbbVie downgraded at Societe Generale on blood cancer and aesthetics headwinds
11/08/22 Societe Generale
AbbVie downgraded to Hold from Buy at Societe Generale
10/28/22 Piper Sandler
Piper keeps Overweight rating on AbbVie despite 'rough' Q3 report
BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
AMGN Amgen
$289.92 /

+2.63 (+0.92%)

11/17/22 Credit Suisse
Amgen initiated with an Underperform at Credit Suisse
11/08/22 Oppenheimer
Amgen price target raised to $300 from $290 at Oppenheimer
11/08/22 Truist
Amgen price target raised to $280 from $266 at Truist
11/04/22 Piper Sandler
Amgen price target raised to $278 from $265 at Piper Sandler
RHHBY Roche
$40.15 /

-0.03 (-0.07%)

11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
11/15/22 Stifel
Roche downgraded to Hold from Buy at Stifel
11/15/22 Cowen
Roche downgraded to Market Perform on 'bare' pipeline at Cowen
REGN Regeneron
$730.87 /

-8.72 (-1.18%)

11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
11/09/22 Truist
Regeneron price target raised to $856 from $790 at Truist
11/03/22 Piper Sandler
Regeneron price target lowered to $765 from $775 at Piper Sandler
10/31/22 EF Hutton
Regeneron initiated with a Buy at EF Hutton
RHHBY Roche
$40.15 /

-0.03 (-0.07%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

LCTX Lineage Cell Therapeutics
$1.45 /

+0.02 (+1.40%)

IMUX Immunic
$1.39 /

-0.015 (-1.07%)

EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

CTMX CytomX Therapeutics
$1.73 /

+ (+0.00%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

AGIO Agios Pharmaceuticals
$28.81 /

+0.59 (+2.09%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

RHHBY Roche
$40.15 /

-0.03 (-0.07%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

LCTX Lineage Cell Therapeutics
$1.45 /

+0.02 (+1.40%)

IMUX Immunic
$1.39 /

-0.015 (-1.07%)

EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

CTMX CytomX Therapeutics
$1.73 /

+ (+0.00%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

IMUX Immunic
$1.39 /

-0.015 (-1.07%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

Initiation
Bristol-Myers initiated with a Neutral at Credit Suisse » 16:15
11/17/22
11/17
16:15
11/17/22
16:15
BMY

Bristol-Myers

$77.22 /

+1.04 (+1.37%)

Credit Suisse analyst…

Credit Suisse analyst Trung Huynh initiated coverage of Bristol-Myers with a Neutral rating and $78 price target. The analyst expects downward consensus revisions for Bristol's new launch products from a mix of access and competition. Despite the company's "relatively attractive pipeline, we do not see multiple expansion any time soon," Huynh tells investors in a research note.

ShowHide Related Items >><<
BMY Bristol-Myers
$77.22 /

+1.04 (+1.37%)

BMY Bristol-Myers
$77.22 /

+1.04 (+1.37%)

11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
10/31/22 Guggenheim
2seventy Bio initiated with a Buy at Guggenheim
BMY Bristol-Myers
$77.22 /

+1.04 (+1.37%)

BMY Bristol-Myers
$77.22 /

+1.04 (+1.37%)

BMY Bristol-Myers
$77.22 /

+1.04 (+1.37%)

BMY Bristol-Myers
$77.22 /

+1.04 (+1.37%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:07
11/17/22
11/17
10:07
11/17/22
10:07
TGT

Target

$153.45 /

-2.05 (-1.32%)

, NVDA

Nvidia

$160.57 /

+1.17 (+0.73%)

, XPEV

XPeng

$7.76 /

-0.27 (-3.36%)

, ICE

IntercontinentalExchange

$103.91 /

-0.05 (-0.05%)

, BKI

Black Knight

$59.35 /

-0.36 (-0.60%)

, PNW

Pinnacle West

$72.39 /

-0.88 (-1.20%)

, CRM

Salesforce

$150.55 /

-4.57 (-2.95%)

, NIO

Nio

$10.19 /

-0.35 (-3.32%)

, NCLH

Norwegian Cruise Line

$16.13 /

-1.47 (-8.35%)

, RCL

Royal Caribbean

$58.02 /

-2.11 (-3.51%)

, DGX

Quest Diagnostics

$144.53 /

-4.67 (-3.13%)

, EL

Estee Lauder

$220.00 /

-2.9 (-1.30%)

, MIDD

Middleby

$138.28 /

-1.71 (-1.22%)

, WHR

Whirlpool

$144.83 /

-2.79 (-1.89%)

, FC

Franklin Covey

$49.16 /

-0.21 (-0.43%)

, VTYX

Ventyx Biosciences

$25.66 /

+0.25 (+0.98%)

, BMY

Bristol-Myers

$76.67 /

+0.49 (+0.64%)

Institutional investors…

ShowHide Related Items >><<
XPEV XPeng
$7.76 /

-0.27 (-3.36%)

WHR Whirlpool
$144.83 /

-2.79 (-1.89%)

VTYX Ventyx Biosciences
$25.66 /

+0.25 (+0.98%)

TGT Target
$153.45 /

-2.05 (-1.32%)

RCL Royal Caribbean
$58.02 /

-2.11 (-3.51%)

NVDA Nvidia
$160.57 /

+1.17 (+0.73%)

NIO Nio
$10.19 /

-0.35 (-3.32%)

NCLH Norwegian Cruise Line
$16.13 /

-1.47 (-8.35%)

MIDD Middleby
$138.28 /

-1.71 (-1.22%)

ICE IntercontinentalExchange
$103.91 /

-0.05 (-0.05%)

FC Franklin Covey
$49.16 /

-0.21 (-0.43%)

EL Estee Lauder
$220.00 /

-2.9 (-1.30%)

DGX Quest Diagnostics
$144.53 /

-4.67 (-3.13%)

CRM Salesforce
$150.55 /

-4.57 (-2.95%)

BMY Bristol-Myers
$76.67 /

+0.49 (+0.64%)

BKI Black Knight
$59.35 /

-0.36 (-0.60%)

TGT Target
$153.45 /

-2.05 (-1.32%)

11/17/22 Truist
Target price target lowered to $151 from $165 at Truist
11/17/22 Morgan Stanley
Target price target lowered to $155 from $190 at Morgan Stanley
11/17/22 DA Davidson
Target price target lowered to $180 from $185 at DA Davidson
11/17/22 Raymond James
Target price target lowered to $185 from $200 at Raymond James
NVDA Nvidia
$160.57 /

+1.17 (+0.73%)

11/17/22 Needham
Nvidia price target raised to $200 from $155 at Needham
11/17/22 Jefferies
Nvidia fundamentals bottoming, should grow through 2023, says Jefferies
11/17/22 Stifel
Nvidia price target raised to $175 from $165 at Stifel
11/17/22 Wedbush
Nvidia price target raised to $175 from $160 at Wedbush
XPEV XPeng
$7.76 /

-0.27 (-3.36%)

11/17/22 UBS
XPeng upgraded to Buy from Neutral at UBS
10/28/22 Citi
Citi double downgrades XPeng on 'serious challenges' in 2023
10/28/22 Citi
XPeng downgraded to Sell from Buy at Citi
10/28/22 Barclays
XPeng price target lowered to $8 from $22 at Barclays
ICE IntercontinentalExchange
$103.91 /

-0.05 (-0.05%)

11/17/22 BofA
IntercontinentalExchange upgraded to Buy from Neutral at BofA
11/17/22 BofA
IntercontinentalExchange upgraded to Buy from Neutral at BofA
11/15/22 Deutsche Bank
IntercontinentalExchange price target raised to $124 from $123 at Deutsche Bank
10/12/22 Deutsche Bank
IntercontinentalExchange price target lowered to $122 from $131 at Deutsche Bank
BKI Black Knight
$59.35 /

-0.36 (-0.60%)

05/20/22 Jefferies
IntercontinentalExchange price target lowered to $134 from $161 at Jefferies
05/08/22 Keefe Bruyette
Black Knight downgraded to Market Perform from Outperform at Keefe Bruyette
05/06/22 Deutsche Bank
IntercontinentalExchange shares 'exceptionally attractive,' says Deutsche Bank
PNW Pinnacle West
$72.39 /

-0.88 (-1.20%)

11/17/22 Wolfe Research
Pinnacle West upgraded to Peer Perform at Wolfe on better view in Arizona
11/17/22 Wolfe Research
Pinnacle West upgraded to Peer Perform from Underperform at Wolfe Research
10/24/22 Guggenheim
Pinnacle West price target lowered to $54 from $60 at Guggenheim
10/20/22 KeyBanc
Pinnacle West price target lowered to $56 from $62 at KeyBanc
CRM Salesforce
$150.55 /

-4.57 (-2.95%)

11/17/22 Monness Crespi
Salesforce downgraded to Neutral from Buy at Monness Crespi
11/17/22 Morgan Stanley
ServiceNow named a 'Top Pick' at Morgan Stanley
11/15/22 Mizuho
Salesforce price target lowered to $225 from $235 at Mizuho
11/10/22 Oppenheimer
Salesforce price target lowered to $200 from $240 at Oppenheimer
NIO Nio
$10.19 /

-0.35 (-3.32%)

11/17/22 UBS
Nio downgraded to Neutral at UBS on expectations for ET5 execution challenges
11/17/22 UBS
Nio downgraded to Neutral from Buy at UBS
11/17/22 Barclays
Nio price target lowered to $18 from $19 at Barclays
11/14/22 China Renaissance
Nio downgraded to Hold from Buy at China Renaissance
NCLH Norwegian Cruise Line
$16.13 /

-1.47 (-8.35%)

11/17/22 Credit Suisse
Norwegian Cruise downgraded to Underperform from Outperform at Credit Suisse
11/14/22 UBS
Norwegian Cruise Line price target raised to $24 from $15 at UBS
11/11/22 Deutsche Bank
Norwegian Cruise Line price target lowered to $14 from $16 at Deutsche Bank
11/09/22 Credit Suisse
Norwegian Cruise Line price target lowered to $20 from $25 at Credit Suisse
RCL Royal Caribbean
$58.02 /

-2.11 (-3.51%)

11/14/22 UBS
Royal Caribbean price target raised to $76 from $56 at UBS
10/21/22 Tigress Financial
Royal Caribbean shares have upside to $80, says Tigress Financial
10/12/22 UBS
Royal Caribbean price target lowered to $56 from $65 at UBS
DGX Quest Diagnostics
$144.53 /

-4.67 (-3.13%)

11/17/22 Citi
Quest Diagnostics downgraded to Sell from Neutral at Citi
10/21/22 Deutsche Bank
Quest Diagnostics price target raised to $140 from $129 at Deutsche Bank
08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
EL Estee Lauder
$220.00 /

-2.9 (-1.30%)

11/17/22 Canaccord
Canaccord starts Estee Lauder with Hold, sees estimate risk
11/16/22 Canaccord
Estee Lauder initiated with a Hold at Canaccord
11/16/22 Wells Fargo
Estee Lauder price target raised to $250 from $225 at Wells Fargo
11/16/22 BofA
Estee Lauder price target raised to $230 from $215 at BofA
MIDD Middleby
$138.28 /

-1.71 (-1.22%)

11/17/22 Canaccord
Canaccord starts Middleby with Buy on deferred spending benefits
11/16/22 Canaccord
Middleby initiated with a Buy at Canaccord
11/11/22 Baird
Middleby price target lowered to $140 from $145 at Baird
09/29/22 Baird
Middleby competitor guidance raise a positive, says Baird
WHR Whirlpool
$144.83 /

-2.79 (-1.89%)

11/17/22 Goldman Sachs
Whirlpool reinstated with a Neutral at Goldman Sachs
10/26/22 BofA
Whirlpool downgraded to Underperform at BofA amid 'severe drop' in demand
10/26/22 BofA
Whirlpool downgraded to Underperform from Neutral at BofA
07/15/22 JPMorgan
Whirlpool price target lowered to $191 from $227 at JPMorgan
FC Franklin Covey
$49.16 /

-0.21 (-0.43%)

11/17/22 Northland
Franklin Covey initiated with an Outperform at Northland
01/07/22 Barrington
Franklin Covey price target raised to $60 from $55 at Barrington
VTYX Ventyx Biosciences
$25.66 /

+0.25 (+0.98%)

11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
10/13/22 Piper Sandler
Ventyx Biosciences named a top pick for 2023 at Piper Sandler
09/16/22 Stifel
Ventyx Biosciences price target raised to $53 from $45 at Stifel
09/13/22 H.C. Wainwright
Ventyx Biosciences price target raised to $50 from $36 at H.C. Wainwright
BMY Bristol-Myers
$76.67 /

+0.49 (+0.64%)

11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
10/31/22 Guggenheim
2seventy Bio initiated with a Buy at Guggenheim
XPEV XPeng
$7.76 /

-0.27 (-3.36%)

WHR Whirlpool
$144.83 /

-2.79 (-1.89%)

VTYX Ventyx Biosciences
$25.66 /

+0.25 (+0.98%)

TGT Target
$153.45 /

-2.05 (-1.32%)

RCL Royal Caribbean
$58.02 /

-2.11 (-3.51%)

PNW Pinnacle West
$72.39 /

-0.88 (-1.20%)

NVDA Nvidia
$160.57 /

+1.17 (+0.73%)

NIO Nio
$10.19 /

-0.35 (-3.32%)

NCLH Norwegian Cruise Line
$16.13 /

-1.47 (-8.35%)

MIDD Middleby
$138.28 /

-1.71 (-1.22%)

ICE IntercontinentalExchange
$103.91 /

-0.05 (-0.05%)

FC Franklin Covey
$49.16 /

-0.21 (-0.43%)

EL Estee Lauder
$220.00 /

-2.9 (-1.30%)

DGX Quest Diagnostics
$144.53 /

-4.67 (-3.13%)

CRM Salesforce
$150.55 /

-4.57 (-2.95%)

BMY Bristol-Myers
$76.67 /

+0.49 (+0.64%)

BKI Black Knight
$59.35 /

-0.36 (-0.60%)

XPEV XPeng
$7.76 /

-0.27 (-3.36%)

TGT Target
$153.45 /

-2.05 (-1.32%)

RCL Royal Caribbean
$58.02 /

-2.11 (-3.51%)

NVDA Nvidia
$160.57 /

+1.17 (+0.73%)

NIO Nio
$10.19 /

-0.35 (-3.32%)

NCLH Norwegian Cruise Line
$16.13 /

-1.47 (-8.35%)

ICE IntercontinentalExchange
$103.91 /

-0.05 (-0.05%)

EL Estee Lauder
$220.00 /

-2.9 (-1.30%)

CRM Salesforce
$150.55 /

-4.57 (-2.95%)

BMY Bristol-Myers
$76.67 /

+0.49 (+0.64%)

XPEV XPeng
$7.76 /

-0.27 (-3.36%)

WHR Whirlpool
$144.83 /

-2.79 (-1.89%)

VTYX Ventyx Biosciences
$25.66 /

+0.25 (+0.98%)

TGT Target
$153.45 /

-2.05 (-1.32%)

RCL Royal Caribbean
$58.02 /

-2.11 (-3.51%)

PNW Pinnacle West
$72.39 /

-0.88 (-1.20%)

NVDA Nvidia
$160.57 /

+1.17 (+0.73%)

NIO Nio
$10.19 /

-0.35 (-3.32%)

NCLH Norwegian Cruise Line
$16.13 /

-1.47 (-8.35%)

MIDD Middleby
$138.28 /

-1.71 (-1.22%)

ICE IntercontinentalExchange
$103.91 /

-0.05 (-0.05%)

FC Franklin Covey
$49.16 /

-0.21 (-0.43%)

EL Estee Lauder
$220.00 /

-2.9 (-1.30%)

DGX Quest Diagnostics
$144.53 /

-4.67 (-3.13%)

CRM Salesforce
$150.55 /

-4.57 (-2.95%)

BMY Bristol-Myers
$76.67 /

+0.49 (+0.64%)

XPEV XPeng
$7.76 /

-0.27 (-3.36%)

WHR Whirlpool
$144.83 /

-2.79 (-1.89%)

VTYX Ventyx Biosciences
$25.66 /

+0.25 (+0.98%)

TGT Target
$153.45 /

-2.05 (-1.32%)

RCL Royal Caribbean
$58.02 /

-2.11 (-3.51%)

NVDA Nvidia
$160.57 /

+1.17 (+0.73%)

NIO Nio
$10.19 /

-0.35 (-3.32%)

NCLH Norwegian Cruise Line
$16.13 /

-1.47 (-8.35%)

EL Estee Lauder
$220.00 /

-2.9 (-1.30%)

CRM Salesforce
$150.55 /

-4.57 (-2.95%)

BMY Bristol-Myers
$76.67 /

+0.49 (+0.64%)

Initiation
Ventyx Biosciences initiated with an Overweight at Morgan Stanley » 07:56
11/17/22
11/17
07:56
11/17/22
07:56
VTYX

Ventyx Biosciences

$25.42 /

-0.42 (-1.63%)

, BMY

Bristol-Myers

$76.17 /

-0.115 (-0.15%)

Morgan Stanley analyst…

Morgan Stanley analyst Matthew Harrison initiated coverage of Ventyx Biosciences (VTYX) with an Overweight rating and $45 price target. Ventyx's lead asset, VTX958, is a "potential best-in-class" TYK2 inhibitor for psoriatic and irritable bowel diseases, said Harrison, who points to Bristol-Myers' (BMY) Sotyktu, which has consensus peak sales estimates of about $4B, as highlighting the commercial potential for VTX958. He does not believe Sotyktu has a best-in-class profile as it suffers from a narrow therapeutic window and Harrison said is VTX958 being developed to have a wide therapeutic window.

ShowHide Related Items >><<
VTYX Ventyx Biosciences
$25.42 /

-0.42 (-1.63%)

BMY Bristol-Myers
$76.17 /

-0.115 (-0.15%)

VTYX Ventyx Biosciences
$25.42 /

-0.42 (-1.63%)

10/13/22 Piper Sandler
Ventyx Biosciences named a top pick for 2023 at Piper Sandler
09/16/22 Stifel
Ventyx Biosciences price target raised to $53 from $45 at Stifel
09/13/22 H.C. Wainwright
Ventyx Biosciences price target raised to $50 from $36 at H.C. Wainwright
09/12/22 Evercore ISI
Evercore expecting 'strong move' in Ventyx after Deucravacitinib label surprise
BMY Bristol-Myers
$76.17 /

-0.115 (-0.15%)

11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
10/31/22 Guggenheim
2seventy Bio initiated with a Buy at Guggenheim
10/12/22 Barclays
Bristol-Myers price target lowered to $66 from $69 at Barclays
VTYX Ventyx Biosciences
$25.42 /

-0.42 (-1.63%)

BMY Bristol-Myers
$76.17 /

-0.115 (-0.15%)

BMY Bristol-Myers
$76.17 /

-0.115 (-0.15%)

VTYX Ventyx Biosciences
$25.42 /

-0.42 (-1.63%)

BMY Bristol-Myers
$76.17 /

-0.115 (-0.15%)

VTYX Ventyx Biosciences
$25.42 /

-0.42 (-1.63%)

BMY Bristol-Myers
$76.17 /

-0.115 (-0.15%)

Downgrade
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital » 05:20
11/14/22
11/14
05:20
11/14/22
05:20
CTMX

CytomX Therapeutics

$1.28 /

+0.02 (+1.59%)

, BMY

Bristol-Myers

$75.92 /

-3.44 (-4.33%)

BMO Capital analyst Etzer…

BMO Capital analyst Etzer Darout downgraded CytomX Therapeutics (CTMX) to Market Perform from Outperform with a price target of $2.60, down from $3. The analyst has become more cautious on CX-2029's opportunity after revisiting antibody-drug conjugates non-small lung cancer responses. In addition, he lacks "visibility and strong conviction" on Bristol-Myers' (BMY) CTLA-4 Probody programs and says CytomX's internal pipeline is "far away from meaningful data."

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$1.28 /

+0.02 (+1.59%)

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

CTMX CytomX Therapeutics
$1.28 /

+0.02 (+1.59%)

11/10/22 JPMorgan
JPMorgan double downgrades 'show-me-story' CytomX Therapeutics
11/10/22 JPMorgan
CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan
07/11/22 Cowen
CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen
07/11/22 H.C. Wainwright
CytomX Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
10/31/22 Guggenheim
2seventy Bio initiated with a Buy at Guggenheim
10/12/22 Barclays
Bristol-Myers price target lowered to $66 from $69 at Barclays
10/10/22 Guggenheim
Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials
CTMX CytomX Therapeutics
$1.28 /

+0.02 (+1.59%)

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

CTMX CytomX Therapeutics
$1.28 /

+0.02 (+1.59%)

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

Conference/Events
Society for Immunotherapy of Cancer to hold a meeting » 04:55
11/12/22
11/12
04:55
11/12/22
04:55
ABMD

Abiomed

$373.89 /

+1.235 (+0.33%)

, ADPT

Adaptive Biotechnologies

$9.32 /

+0.23 (+2.53%)

, ALKS

Alkermes

$23.57 /

-0.685 (-2.82%)

, AMGN

Amgen

$284.92 /

-6.02 (-2.07%)

, ASND

Ascendis Pharma

$131.96 /

+2.47 (+1.91%)

, BMY

Bristol-Myers

$75.92 /

-3.44 (-4.33%)

, CGEN

Compugen

/

+

, CLRB

Cellectar Biosciences

$1.90 /

+0.01 (+0.53%)

, CRL

Charles River

$246.43 /

+8.49 (+3.57%)

, INKT

MiNK Therapeutics

$2.99 /

+0.81 (+37.16%)

, INCY

Incyte

$77.54 /

-0.21 (-0.27%)

, PHIO

Phio Pharmaceuticals

/

+

, INBX

Inhibrx

$32.72 /

+0.57 (+1.77%)

, XNCR

Xencor

$29.42 /

-1.07 (-3.51%)

, VCYT

Veracyte

$29.95 /

+1.915 (+6.83%)

, TXG

10x Genomics

$41.29 /

+3.51 (+9.29%)

, TPST

Tempest Therapeutics

$1.73 /

+0.2 (+13.07%)

, TMO

Thermo Fisher

$539.07 /

+18.83 (+3.62%)

, TIL

Instil Bio

$2.26 /

-0.16 (-6.63%)

, SGEN

Seagen

$132.82 /

+1.77 (+1.35%)

, REGN

Regeneron

$734.49 /

-7.28 (-0.98%)

, REPL

Replimune Group

$21.02 /

+0.89 (+4.42%)

, RHHBY

Roche

$43.25 /

+0.72 (+1.69%)

, DNA

Ginkgo Bioworks

$2.86 /

+0.225 (+8.56%)

, CUE

Cue Biopharma

$3.11 /

+0.03 (+0.97%)

, IOVA

Iovance Biotherapeutics

$8.87 /

+0.205 (+2.37%)

, IPSC

Century Therapeutics

$10.95 /

-0.64 (-5.52%)

, LH

Labcorp

$249.20 /

+6.07 (+2.50%)

, MRK

Merck

$97.90 /

-3.91 (-3.84%)

, MXCT

MaxCyte

$7.13 /

+0.085 (+1.21%)

, EXEL

Exelixis

$16.78 /

-0.105 (-0.62%)

, FATE

Fate Therapeutics

$22.95 /

+1.99 (+9.49%)

, GMAB

Genmab

$41.84 /

-1.67 (-3.84%)

37th Annual Meeting SITC…

37th Annual Meeting SITC 2022 to be held in Boston on November 8-12.

ShowHide Related Items >><<
XNCR Xencor
$29.42 /

-1.07 (-3.51%)

VCYT Veracyte
$29.95 /

+1.915 (+6.83%)

TXG 10x Genomics
$41.29 /

+3.51 (+9.29%)

TPST Tempest Therapeutics
$1.73 /

+0.2 (+13.07%)

TMO Thermo Fisher
$539.07 /

+18.83 (+3.62%)

TIL Instil Bio
$2.26 /

-0.16 (-6.63%)

SGEN Seagen
$132.82 /

+1.77 (+1.35%)

RHHBY Roche
$43.25 /

+0.72 (+1.69%)

REPL Replimune Group
$21.02 /

+0.89 (+4.42%)

REGN Regeneron
$734.49 /

-7.28 (-0.98%)

PHIO Phio Pharmaceuticals
/

+

MXCT MaxCyte
$7.13 /

+0.085 (+1.21%)

MRK Merck
$97.90 /

-3.91 (-3.84%)

LH Labcorp
$249.20 /

+6.07 (+2.50%)

IPSC Century Therapeutics
$10.95 /

-0.64 (-5.52%)

IOVA Iovance Biotherapeutics
$8.87 /

+0.205 (+2.37%)

INKT MiNK Therapeutics
$2.99 /

+0.81 (+37.16%)

INCY Incyte
$77.54 /

-0.21 (-0.27%)

INBX Inhibrx
$32.72 /

+0.57 (+1.77%)

GMAB Genmab
$41.84 /

-1.67 (-3.84%)

FATE Fate Therapeutics
$22.95 /

+1.99 (+9.49%)

EXEL Exelixis
$16.78 /

-0.105 (-0.62%)

DNA Ginkgo Bioworks
$2.86 /

+0.225 (+8.56%)

CUE Cue Biopharma
$3.11 /

+0.03 (+0.97%)

CRL Charles River
$246.43 /

+8.49 (+3.57%)

CLRB Cellectar Biosciences
$1.90 /

+0.01 (+0.53%)

CGEN Compugen
/

+

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

ASND Ascendis Pharma
$131.96 /

+2.47 (+1.91%)

AMGN Amgen
$284.92 /

-6.02 (-2.07%)

ALKS Alkermes
$23.57 /

-0.685 (-2.82%)

ADPT Adaptive Biotechnologies
$9.32 /

+0.23 (+2.53%)

ABMD Abiomed
$373.89 /

+1.235 (+0.33%)

ABMD Abiomed
$373.89 /

+1.235 (+0.33%)

11/02/22 Morgan Stanley
Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/22 Deutsche Bank
Abiomed downgraded to Hold from Buy at Deutsche Bank
11/01/22 William Blair
Abiomed downgraded to Market Perform from Outperform at William Blair
11/01/22 Piper Sandler
Abiomed downgraded to Neutral from Overweight at Piper Sandler
ADPT Adaptive Biotechnologies
$9.32 /

+0.23 (+2.53%)

10/26/22 Piper Sandler
Natera named top pick in minimal residual disease at Piper Sandler
10/26/22 Piper Sandler
Adaptive price target lowered to $7.50 from $12 at Piper Sandler
08/24/22 Credit Suisse
Adaptive Biotechnologies initiated with an Underperform at Credit Suisse
08/17/22 Piper Sandler
Adaptive Biotechnologies price target raised to $12 from $7.50 at Piper Sandler
ALKS Alkermes
$23.57 /

-0.685 (-2.82%)

11/03/22 Piper Sandler
Alkermes upgraded to Overweight from Neutral at Piper Sandler
10/20/22 Mizuho
Alkermes Q3 miss may be largely priced in, says Mizuho
10/19/22 Piper Sandler
Alkermes shares have more downside risk, says Piper Sandler
10/14/22 BofA
Alkermes upgraded to Neutral at BofA on improved risk/reward
AMGN Amgen
$284.92 /

-6.02 (-2.07%)

11/08/22 Oppenheimer
Amgen price target raised to $300 from $290 at Oppenheimer
11/08/22 Truist
Amgen price target raised to $280 from $266 at Truist
11/04/22 Piper Sandler
Amgen price target raised to $278 from $265 at Piper Sandler
10/31/22 Barclays
Amgen downgraded to Underweight from Equal Weight at Barclays
ASND Ascendis Pharma
$131.96 /

+2.47 (+1.91%)

11/03/22 Oppenheimer
Ascendis Pharma price target raised to $150 from $144 at Oppenheimer
11/03/22 Wedbush
Ascendis Pharma price target raised to $151 from $144 at Wedbush
11/03/22 Credit Suisse
Ascendis Pharma price target raised to $130 from $123 at Credit Suisse
11/03/22 Citi
Ascendis Pharma price target raised to $163 from $157 at Citi
BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
10/31/22 Guggenheim
2seventy Bio initiated with a Buy at Guggenheim
10/12/22 Barclays
Bristol-Myers price target lowered to $66 from $69 at Barclays
10/10/22 Guggenheim
Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials
CGEN Compugen
/

+

08/23/22 Truist
Compugen price target lowered to $4 from $14 at Truist
08/08/22 JMP Securities
Compugen price target lowered to $4 from $8 at JMP Securities
08/05/22 Jefferies
Jefferies downgrades Compugen to Hold with cash likely becoming 'growing issue'
08/05/22 Jefferies
Compugen downgraded to Hold from Buy at Jefferies
CLRB Cellectar Biosciences
$1.90 /

+0.01 (+0.53%)

11/08/22 Maxim
Cellectar Biosciences price target lowered to $7 from $12.50 at Maxim
11/04/22 Oppenheimer
Cellectar Biosciences price target lowered to $12 from $47 at Oppenheimer
07/18/22 Oppenheimer
Cellectar Biosciences assumed with an Outperform at Oppenheimer
04/07/22 Ladenburg
Cellectar Biosciences transferred with a Buy at Ladenburg
CRL Charles River
$246.43 /

+8.49 (+3.57%)

11/03/22 Credit Suisse
Charles River price target lowered to $280 from $285 at Credit Suisse
09/30/22 Jefferies
Charles River upgraded to Buy at Jefferies on nonhuman primate tailwinds
09/29/22 Jefferies
Charles River upgraded to Buy from Hold at Jefferies
08/24/22 Credit Suisse
Charles River initiated with an Outperform at Credit Suisse
INKT MiNK Therapeutics
$2.99 /

+0.81 (+37.16%)

08/10/22 H.C. Wainwright
MiNK Therapeutics initiated with a Buy at H.C. Wainwright
05/11/22 B. Riley
MiNK Therapeutics price target lowered to $7 from $10 at B. Riley
01/24/22 B. Riley
MiNK Therapeutics price target lowered to $10 from $24 at B. Riley
INCY Incyte
$77.54 /

-0.21 (-0.27%)

10/24/22 JPMorgan
Incyte price target lowered to $80 from $86 at JPMorgan
08/03/22 Evercore ISI
Incyte downgraded to In Line from Outperform at Evercore ISI
08/03/22 Guggenheim
Incyte downgraded to Neutral at Guggenheim after Opzelura Q2 miss
08/03/22 Oppenheimer
Incyte price target lowered to $98 from $109 at Oppenheimer
PHIO Phio Pharmaceuticals
/

+

INBX Inhibrx
$32.72 /

+0.57 (+1.77%)

10/05/22 Evercore ISI
Inhibrx price target raised to $60 from $54 at Evercore ISI
08/09/22 Credit Suisse
Inhibrx price target lowered to $48 from $53 at Credit Suisse
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
XNCR Xencor
$29.42 /

-1.07 (-3.51%)

11/09/22 Canaccord
Xencor price target lowered to $48 from $50 at Canaccord
11/08/22 Raymond James
Xencor added to Analyst Current Favorites list at Raymond James
10/13/22 Raymond James
Xencor upgraded to Strong Buy from Outperform at Raymond James
10/13/22 Raymond James
Xencor upgraded to Strong Buy from Outperform at Raymond James
VCYT Veracyte
$29.95 /

+1.915 (+6.83%)

05/04/22 Needham
Veracyte price target lowered to $26 from $31 at Needham
03/15/22 Needham
Needham drops Veracyte target, says shares undervalued
03/01/22 Lake Street
Veracyte price target lowered to $50 from $95 at Lake Street
03/01/22 Needham
Veracyte price target lowered to $35 from $55 at Needham
TXG 10x Genomics
$41.29 /

+3.51 (+9.29%)

11/03/22 JPMorgan
10x Genomics price target lowered to $55 from $65 at JPMorgan
08/18/22 Goldman Sachs
10x Genomics downgraded to Sell from Neutral at Goldman Sachs
08/11/22 Piper Sandler
Illumina miss 'surprising' given backlog, says Piper Sandler
08/10/22 Morgan Stanley
10x Genomics price target lowered to $70 from $100 at Morgan Stanley
TPST Tempest Therapeutics
$1.73 /

+0.2 (+13.07%)

09/15/22 Ladenburg
Tempest Therapeutics initiated with a Buy at Ladenburg
05/13/22 Piper Sandler
Tempest Therapeutics price target lowered to $10 from $20 at Piper Sandler
05/13/22 H.C. Wainwright
Tempest Therapeutics price target lowered to $35 from $51 at H.C. Wainwright
04/27/22 Piper Sandler
Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20
TMO Thermo Fisher
$539.07 /

+18.83 (+3.62%)

11/01/22 Baird
Thermo Fisher price target lowered to $665 from $695 at Baird
10/27/22 Morgan Stanley
Thermo Fisher price target lowered to $613 from $678 at Morgan Stanley
10/27/22 Baird
Thermo Fisher price target lowered to $696 from $711 at Baird
10/27/22 Citi
Thermo Fisher price target lowered to $650 from $715 at Citi
TIL Instil Bio
$2.26 /

-0.16 (-6.63%)

11/01/22 Cowen
Cowen downgrades Instil Bio on manufacturing failures
11/01/22 Truist
Instil Bio downgraded to Hold from Buy at Truist
11/01/22 Baird
Instil Bio price target lowered to $24 from $31 at Baird
11/01/22 Cowen
Instil Bio downgraded to Market Perform from Outperform at Cowen
SGEN Seagen
$132.82 /

+1.77 (+1.35%)

10/28/22 Oppenheimer
Seagen price target lowered to $188 from $208 at Oppenheimer
10/28/22 H.C. Wainwright
Seagen price target lowered to $180 from $200 at H.C. Wainwright
10/24/22 JPMorgan
Seagen price target lowered to $155 from $194 at JPMorgan
10/11/22 BMO Capital
Seagen upgraded to Outperform from Market Perform at BMO Capital
REGN Regeneron
$734.49 /

-7.28 (-0.98%)

11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
11/09/22 Truist
Regeneron price target raised to $856 from $790 at Truist
11/03/22 Piper Sandler
Regeneron price target lowered to $765 from $775 at Piper Sandler
10/31/22 EF Hutton
Regeneron initiated with a Buy at EF Hutton
REPL Replimune Group
$21.02 /

+0.89 (+4.42%)

10/14/22 BMO Capital
Replimune Group price target raised to $40 from $30 at BMO Capital
08/16/22 Piper Sandler
Replimune Group price target lowered to $43 from $44 at Piper Sandler
05/24/22 Wedbush
Replimune Group price target lowered to $52 from $59 at Wedbush
05/19/22 Piper Sandler
Replimune Group price target lowered to $44 from $52 at Piper Sandler
RHHBY Roche
$43.25 /

+0.72 (+1.69%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
10/25/22 Capital One
Arvinas initiated with an Overweight at Capital One
10/17/22 Morgan Stanley
Roche's AD drug expected to fall short in trial, says Morgan Stanley
10/12/22 Stifel
Biogen upgraded to Buy from Hold at Stifel
DNA Ginkgo Bioworks
$2.86 /

+0.225 (+8.56%)

10/04/22 Morgan Stanley
Ginkgo Bioworks initiated with an Equal Weight at Morgan Stanley
08/16/22 BTIG
Ginkgo Bioworks price target raised to $6 from $5 at BTIG
08/16/22 Raymond James
Ginkgo Bioworks price target raised to $14.50 from $11.50 at Raymond James
07/26/22 William Blair
Zymergen buyout deal 'best case scenario,' says William Blair
CUE Cue Biopharma
$3.11 /

+0.03 (+0.97%)

11/10/22 Oppenheimer
Cue Biopharma's SITC data a 'big improvement,' says Oppenheimer
08/24/22 Oppenheimer
Cue Biopharma price target lowered to $10 from $26 at Oppenheimer
03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
IOVA Iovance Biotherapeutics
$8.87 /

+0.205 (+2.37%)

10/31/22 Guggenheim
Iovance Biotherapeutics initiated with a Neutral at Guggenheim
08/18/22 Wells Fargo
Iovance Biotherapeutics assumed with an Equal Weight at Wells Fargo
08/08/22 Stifel
Global Blood Therapeutics downgraded to Hold from Buy at Stifel
IPSC Century Therapeutics
$10.95 /

-0.64 (-5.52%)

11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
06/10/22 Roth Capital
Century Therapeutics initiated with a Buy at Roth Capital
LH Labcorp
$249.20 /

+6.07 (+2.50%)

11/03/22 Mizuho
Labcorp price target lowered to $250 from $296 at Mizuho
10/28/22 Citi
Labcorp price target lowered to $275 from $300 at Citi
10/28/22 Baird
Labcorp price target lowered to $270 from $297 at Baird
09/19/22 Argus
Labcorp downgraded to Hold from Buy at Argus
MRK Merck
$97.90 /

-3.91 (-3.84%)

11/01/22 Oppenheimer
Merck pact shows Veeva life science vendor of choice, says Oppenheimer
11/01/22 Guggenheim
Merck price target raised to $111 from $104 at Guggenheim
10/28/22 Morgan Stanley
Merck price target raised to $100 from $91 at Morgan Stanley
10/28/22 Cantor Fitzgerald
Merck price target raised to $120 from $107 at Cantor Fitzgerald
MXCT MaxCyte
$7.13 /

+0.085 (+1.21%)

08/14/22 BTIG
MaxCyte price target raised to $11 from $10 at BTIG
EXEL Exelixis
$16.78 /

-0.105 (-0.62%)

11/02/22 Cowen
Exelixis price target lowered to $21 from $26 at Cowen
10/31/22 EF Hutton
Exelixis initiated with a Buy at EF Hutton
10/18/22 JMP Securities
Exelixis initiated with an Outperform at JMP Securities
10/12/22 Guggenheim
Initial data for Exelixis's XB002 show encouraging safety, says Guggenheim
FATE Fate Therapeutics
$22.95 /

+1.99 (+9.49%)

11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
GMAB Genmab
$41.84 /

-1.67 (-3.84%)

11/11/22 Deutsche Bank
Genmab downgraded to Hold at Deutsche Bank ahead of ESMO and ASH data
11/11/22 Deutsche Bank
Genmab downgraded to Hold from Buy at Deutsche Bank
10/17/22 DNB Markets
Genmab downgraded to Hold from Buy at DNB Markets
09/15/22 Credit Suisse
Genmab price target raised to DKK 2,800 from DKK 2,600 at Credit Suisse
XNCR Xencor
$29.42 /

-1.07 (-3.51%)

VCYT Veracyte
$29.95 /

+1.915 (+6.83%)

TXG 10x Genomics
$41.29 /

+3.51 (+9.29%)

TPST Tempest Therapeutics
$1.73 /

+0.2 (+13.07%)

TMO Thermo Fisher
$539.07 /

+18.83 (+3.62%)

TIL Instil Bio
$2.26 /

-0.16 (-6.63%)

SGEN Seagen
$132.82 /

+1.77 (+1.35%)

RHHBY Roche
$43.25 /

+0.72 (+1.69%)

REPL Replimune Group
$21.02 /

+0.89 (+4.42%)

REGN Regeneron
$734.49 /

-7.28 (-0.98%)

MXCT MaxCyte
$7.13 /

+0.085 (+1.21%)

MRK Merck
$97.90 /

-3.91 (-3.84%)

LH Labcorp
$249.20 /

+6.07 (+2.50%)

IPSC Century Therapeutics
$10.95 /

-0.64 (-5.52%)

IOVA Iovance Biotherapeutics
$8.87 /

+0.205 (+2.37%)

INKT MiNK Therapeutics
$2.99 /

+0.81 (+37.16%)

INCY Incyte
$77.54 /

-0.21 (-0.27%)

INBX Inhibrx
$32.72 /

+0.57 (+1.77%)

GMAB Genmab
$41.84 /

-1.67 (-3.84%)

FATE Fate Therapeutics
$22.95 /

+1.99 (+9.49%)

EXEL Exelixis
$16.78 /

-0.105 (-0.62%)

DNA Ginkgo Bioworks
$2.86 /

+0.225 (+8.56%)

CRL Charles River
$246.43 /

+8.49 (+3.57%)

CLRB Cellectar Biosciences
$1.90 /

+0.01 (+0.53%)

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

ASND Ascendis Pharma
$131.96 /

+2.47 (+1.91%)

AMGN Amgen
$284.92 /

-6.02 (-2.07%)

ALKS Alkermes
$23.57 /

-0.685 (-2.82%)

ADPT Adaptive Biotechnologies
$9.32 /

+0.23 (+2.53%)

ABMD Abiomed
$373.89 /

+1.235 (+0.33%)

TMO Thermo Fisher
$539.07 /

+18.83 (+3.62%)

SGEN Seagen
$132.82 /

+1.77 (+1.35%)

REGN Regeneron
$734.49 /

-7.28 (-0.98%)

MRK Merck
$97.90 /

-3.91 (-3.84%)

LH Labcorp
$249.20 /

+6.07 (+2.50%)

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

AMGN Amgen
$284.92 /

-6.02 (-2.07%)

XNCR Xencor
$29.42 /

-1.07 (-3.51%)

VCYT Veracyte
$29.95 /

+1.915 (+6.83%)

TXG 10x Genomics
$41.29 /

+3.51 (+9.29%)

TMO Thermo Fisher
$539.07 /

+18.83 (+3.62%)

TIL Instil Bio
$2.26 /

-0.16 (-6.63%)

SGEN Seagen
$132.82 /

+1.77 (+1.35%)

RHHBY Roche
$43.25 /

+0.72 (+1.69%)

REGN Regeneron
$734.49 /

-7.28 (-0.98%)

MRK Merck
$97.90 /

-3.91 (-3.84%)

LH Labcorp
$249.20 /

+6.07 (+2.50%)

IOVA Iovance Biotherapeutics
$8.87 /

+0.205 (+2.37%)

INKT MiNK Therapeutics
$2.99 /

+0.81 (+37.16%)

INCY Incyte
$77.54 /

-0.21 (-0.27%)

INBX Inhibrx
$32.72 /

+0.57 (+1.77%)

FATE Fate Therapeutics
$22.95 /

+1.99 (+9.49%)

EXEL Exelixis
$16.78 /

-0.105 (-0.62%)

DNA Ginkgo Bioworks
$2.86 /

+0.225 (+8.56%)

CUE Cue Biopharma
$3.11 /

+0.03 (+0.97%)

CRL Charles River
$246.43 /

+8.49 (+3.57%)

CGEN Compugen
/

+

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

ASND Ascendis Pharma
$131.96 /

+2.47 (+1.91%)

AMGN Amgen
$284.92 /

-6.02 (-2.07%)

ALKS Alkermes
$23.57 /

-0.685 (-2.82%)

ADPT Adaptive Biotechnologies
$9.32 /

+0.23 (+2.53%)

ABMD Abiomed
$373.89 /

+1.235 (+0.33%)

TMO Thermo Fisher
$539.07 /

+18.83 (+3.62%)

SGEN Seagen
$132.82 /

+1.77 (+1.35%)

REGN Regeneron
$734.49 /

-7.28 (-0.98%)

MRK Merck
$97.90 /

-3.91 (-3.84%)

IPSC Century Therapeutics
$10.95 /

-0.64 (-5.52%)

IOVA Iovance Biotherapeutics
$8.87 /

+0.205 (+2.37%)

DNA Ginkgo Bioworks
$2.86 /

+0.225 (+8.56%)

CRL Charles River
$246.43 /

+8.49 (+3.57%)

BMY Bristol-Myers
$75.92 /

-3.44 (-4.33%)

AMGN Amgen
$284.92 /

-6.02 (-2.07%)

ABMD Abiomed
$373.89 /

+1.235 (+0.33%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.